Biotech News

Regeneron to Highlight Progress Across Its Metabolic Disease, Ophthalmology and Rare Disease Pipelines at ADA and ENDO

Regeneron Pharmaceuticals (REGN)investor.regeneron.com2026-06-04 19:05 ESTCompany update

Latest clinical data and research illustrate Regeneron’s advancement of innovative science for diverse and serious diseases with significant unmet needs TARRYTOWN, N.Y., June 04, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new clinical data and

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals is a biologics-driven biopharmaceutical company built around antibody science, specialty-market execution, and a durable R&D engine. Investors watch both the commercial base and the next wave of pipeline readouts.

Recent company news

REGNRegeneron Pharmaceuticals2026-05-29 00:03:44 EST

Regeneron’s Ebola Antibody Recommended by World Health Organization for Investigational Use in Response to Current Bundibugyo Ebolavirus Outbreak

REGNRegeneron Pharmaceuticals2026-05-22 15:05:36 EST

Otarmeni™ (lunsotogene parvec) Receives EMA Filing Acceptance for Genetic Hearing Loss

REGNRegeneron Pharmaceuticals2026-05-22 01:02:40 EST

Lynozyfic® (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second-Line-Plus Systemic Amyloid Light Chain Amyloidosis

REGNRegeneron Pharmaceuticals2026-05-18 15:01:45 EST

Regeneron Announces Strategic Collaboration with Parabilis Medicines to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States